ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer
Gynecologic Oncology
◽
10.1016/j.ygyno.2019.11.066
◽
2020
◽
Vol 156
(3)
◽
pp. e15-e16
Author(s):
Kathleen G. Essel
◽
Lainie P. Martin
◽
David M. O’Malley
◽
Ursula Matulonis
◽
Jason A. Konner
◽
...
Keyword(s):
Ovarian Cancer
◽
Safety Profile
◽
Folate Receptor
◽
Recurrent Ovarian Cancer
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Antibody Drug
Download Full-text
Related Documents
Cited By
References
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Annals of Oncology
◽
10.1093/annonc/mdz250
◽
2019
◽
Vol 30
◽
pp. v403
◽
Cited By ~ 8
Author(s):
K. Moore
◽
A. Oza
◽
N. Colombo
◽
A. Oaknin
◽
G. Scambia
◽
...
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Phase Iii
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Platinum Resistant
◽
Phase Iii Study
◽
Antibody Drug
Download Full-text
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
Neoplasia
◽
10.1016/j.neo.2016.11.002
◽
2016
◽
Vol 18
(12)
◽
pp. 775-784
◽
Cited By ~ 29
Author(s):
Jose F. Ponte
◽
Olga Ab
◽
Leanne Lanieri
◽
Jenny Lee
◽
Jennifer Coccia
◽
...
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Standard Of Care
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Cancer Models
◽
Antibody Drug
Download Full-text
Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
Annals of Oncology
◽
10.1093/annonc/mdz250.036
◽
2019
◽
Vol 30
◽
pp. v419-v420
Author(s):
D. O'Malley
◽
D. Richardson
◽
I.B. Vergote
◽
L. Gilbert
◽
L.P. Martin
◽
...
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Phase Ib
◽
Receptor Alpha
◽
Drug Conjugate
◽
Initial Results
◽
Antibody Drug
Download Full-text
Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
Gynecologic Oncology
◽
10.1016/j.ygyno.2018.04.085
◽
2018
◽
Vol 149
◽
pp. 38
◽
Cited By ~ 10
Author(s):
U.A. Matulonis
◽
K.N. Moore
◽
L.P. Martin
◽
I.B. Vergote
◽
C.M. Castro
◽
...
Keyword(s):
Ovarian Cancer
◽
Epithelial Ovarian Cancer
◽
Folate Receptor
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Phase Ib
◽
Receptor Alpha
◽
Drug Conjugate
◽
Platinum Resistant
◽
Antibody Drug
Download Full-text
Combination Regimens of Mirvetuximab Soravtansine, A Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, With Standard-Of-Care Agents Offer Promise for the Treatment of Ovarian Cancer
Health Care Current Reviews
◽
10.4172/2375-4273.1000195
◽
2017
◽
Vol 05
(02)
◽
Author(s):
Todd M Bauer
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Standard Of Care
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Combination Regimens
◽
Antibody Drug
Download Full-text
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Gynecologic Oncology
◽
10.1016/j.ygyno.2018.07.017
◽
2018
◽
Vol 151
(1)
◽
pp. 46-52
◽
Cited By ~ 16
Author(s):
Kathleen N. Moore
◽
David M. O'Malley
◽
Ignace Vergote
◽
Lainie P. Martin
◽
Antonio Gonzalez-Martin
◽
...
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Platinum Sensitive
◽
Phase 1B
◽
Antibody Drug
Download Full-text
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
Journal of Clinical Oncology
◽
10.1200/jco.2018.36.15_suppl.5549
◽
2018
◽
Vol 36
(15_suppl)
◽
pp. 5549-5549
Author(s):
David M. O'Malley
◽
Lainie P. Martin
◽
Lucy Gilbert
◽
Ignace Vergote
◽
Ursula A. Matulonis
◽
...
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Activity Profile
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Platinum Resistant
◽
Phase 1B
◽
Antibody Drug
Download Full-text
833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
Annals of Oncology
◽
10.1016/j.annonc.2020.08.972
◽
2020
◽
Vol 31
◽
pp. S626-S627
Author(s):
D.M. O'Malley
◽
D.L. Richardson
◽
I.B. Vergote
◽
L. Gilbert
◽
C. Castro
◽
...
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Platinum Sensitive
◽
Antibody Drug
Download Full-text
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Gynecologic Oncology
◽
10.1016/j.ygyno.2020.01.037
◽
2020
◽
Vol 157
(2)
◽
pp. 379-385
◽
Cited By ~ 7
Author(s):
David M. O'Malley
◽
Ursula A. Matulonis
◽
Michael J. Birrer
◽
Cesar M. Castro
◽
Lucy Gilbert
◽
...
Keyword(s):
Ovarian Cancer
◽
Folate Receptor
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Phase Ib
◽
Receptor Alpha
◽
Drug Conjugate
◽
Platinum Resistant
◽
Antibody Drug
Download Full-text
IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.5567
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. 5567-5567
◽
Cited By ~ 2
Author(s):
Kathleen N. Moore
◽
Lainie P. Martin
◽
Ursula A. Matulonis
◽
Jason A. Konner
◽
Shelly Marie Seward
◽
...
Keyword(s):
Ovarian Cancer
◽
Epithelial Ovarian Cancer
◽
Folate Receptor
◽
Single Agent
◽
Antibody Drug Conjugate
◽
Folate Receptor Alpha
◽
Receptor Alpha
◽
Drug Conjugate
◽
Platinum Resistant
◽
Antibody Drug
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close